It has been suggested that transferred activated DCs result in higher concentrations of IL-15 and the chemokine eotaxin in the tumor, and collectively proposes that a DC-based, active immunotherapeutic strategy in combination with loco-regional treatment exerts beneficial anti-tumor effects against liver cancer and in DFS [63]. The gene discussed is CCL11; the disease is neoplasm.